Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD)

On January 30, 2014, a workshop was held on neuroimaging endpoints in high-grade glioma. This workshop was sponsored by the Jumpstarting Brain Tumor Drug Development Coalition, consisting of the National Brain Tumor Society, the Society for Neuro-Oncology, Accelerate Brain Cancer Cure, and the Musel...

Full description

Saved in:
Bibliographic Details
Published inNeuro-oncology (Charlottesville, Va.) Vol. 16 Suppl 7; no. suppl_7; pp. vii36 - vii47
Main Authors Wen, Patrick Y, Cloughesy, Timothy F, Ellingson, Benjamin M, Reardon, David A, Fine, Howard A, Abrey, Lauren, Ballman, Karla, Bendszuz, Martin, Buckner, Jan, Chang, Susan M, Prados, Michael D, Pope, Whitney B, Gregory Sorensen, Alma, van den Bent, Martin, Yung, Wai-Kwan Alfred
Format Journal Article
LanguageEnglish
Published England Oxford University Press 01.10.2014
Subjects
Brain Neoplasms - diagnosis
Brain Neoplasms - drug therapy
Clinical Trials as Topic
Drug Approval
Endpoint Determination
Glioma - diagnosis
Glioma - therapy
Humans
Magnetic Resonance Imaging - methods
Magnetic Resonance Imaging - trends
Neuroimaging - methods
Neuroimaging - trends
Positron-Emission Tomography - methods
Positron-Emission Tomography - trends
Response Evaluation Criteria in Solid Tumors
brain tumor
endpoints
RANO
workshop
neuroimaging
Online AccessGet full text

Cover

More Information
Summary:On January 30, 2014, a workshop was held on neuroimaging endpoints in high-grade glioma. This workshop was sponsored by the Jumpstarting Brain Tumor Drug Development Coalition, consisting of the National Brain Tumor Society, the Society for Neuro-Oncology, Accelerate Brain Cancer Cure, and the Musella Foundation for Research and Information, and conducted in collaboration with the Food and Drug Administration. The workshop included neuro-oncologists, neuroradiologists, radiation oncologists, neurosurgeons, biostatisticians, patient advocates, and representatives from industry, clinical research organizations, and the National Cancer Institute. This report summarizes the presentations and discussions of that workshop and the proposals that emerged to improve the Response Assessment in Neuro-Oncology (RANO) criteria and standardize neuroimaging parameters.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1522-8517
1523-5866
DOI:10.1093/neuonc/nou226